14 August 2018

Diasorin launches Hepatitis Delta (HDV) Test on Liason XL Platform

DiaSorin receives clearance from the CE Notified Body to market the LIAISON XL Murex Anti-HDV assay for the diagnosis of Hepatitis D virus (HDV) infection enlarging its CLIA menu for hepatitis on LIAISON platforms
08 August 2018

Imfinzi receives positive EU CHMP opinion for locally-advanced, unresectable non-small cell lung cancer

AstraZeneca and MedImmune announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending a marketing authorisation of Imfinzi (durvalumab) for the treatment of locally-advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥1% of tumour cells.
01 August 2018

MolMed approves results at June 30th 2018, significantly improved compared to first half 2017

• +36.9% Revenues from Sales, equal to Euro 12.2 million • Operating Result and Net Result further improved, respectively by 56.1% and 52.7% • Positive Net Financial Position of Euro 18.1 million (Euro 18.1 million as of December 31st 2017)
29 July 2018

Anti-PD-L1 Immunotherapy Plus ABRAXANE® Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassion130 Study

Celgene Corporation announces that the Phase III IMpassion130 study, which was sponsored by Roche, met its co-primary endpoint of progression-free survival (PFS).
25 July 2018

MolMed signs a new, three-year agreement for the development and supply of lentiviral vectors

MolMed, medical biotechnology company focusing on research, development, manufacturing, and clinical validation of Cell & Gene therapies, announces the signing of a three-year agreement, with GSK, science-led global healthcare company, for the development and manufacturing of lentiviral vectors to be used for clinical application in GSK’s oncology programme.
22 July 2018

Axxam Spa is a member of the RESOLUTE Consortium

Axxam announces its participation to the RESOLUTE (Research empowerment on solute carriers) Consortium, a public-private research partnership supported by the Innovative Medicines Initiative (IMI)

Partner

Where to find us

20149 Milan
Via Giovanni da Procida, 11
Show map 
Tel. +39 02.34565.1
Fax. +39 02.34565.310
Segreteria Assobiotec
Tel. 02 34565.256/341
assobiotec@federchimica.it